Bon Natural Life (BON) Stock News

Bon Natural Life (Nasdaq: BON) has secured a significant $16 million non-exclusive distribution agreement with Beijing Huahai Keyuan Technology for its natural prebiotic product series in China. The 24-month agreement focuses on marketing and distributing BON's advanced gut health products featuring a "Prebiotic + Postbiotic" complex with super prebiotic stachyose as the flagship ingredient.

The partnership leverages Huahai Keyuan's strong market presence and commercialization expertise in China's wellness sector. BON's innovative formulation aims to provide rapid and sustained support for gut microbiota, potentially redefining the gut health market while driving growth and shareholder value.

Bon Natural Life (BON) has signed a 36-month non-exclusive distribution agreement with Tianjin Merrill-Youli Trading Co. worth up to $18 million for marketing Ambroxide products in Asia-Pacific. The partnership focuses on the industrial fabric fragrance sector, with Ambroxide being a synthetic, cruelty-free alternative to natural ambergris. The market for Ambroxide is expected to grow by over 25% annually for the next five years. Bon has also developed a biosynthetic alternative to Sclareol, the key ingredient in Ambroxide production, with plans to scale production from thousands to tens of thousands of tons yearly. This technological breakthrough is expected to reduce costs and improve efficiency, positioning Bon to expand beyond perfumery into the larger textile fragrance market.

Bon Natural Life Limited (BON), a bio-ingredient solution provider in the natural, health and personal care industry, has announced a share repurchase program of up to $1.0 million of its Class A ordinary shares. The company will conduct the repurchases in the open market, with timing and volume depending on factors including price, market conditions, corporate requirements, and regulatory compliance. BON has appointed TradeUp Securities as its exclusive agent for executing the purchases. The program can be suspended, modified, or discontinued at any time, and does not obligate the company to purchase any specific number of shares.

Bon Natural Life Limited (BON) has announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade for marketing and distributing BON's tea pigment series health products in China. The agreement spans 24 months with a total contract value of $24 million.

The company's tea pigments, which offer benefits in lipid modulation, glycemic control, antioxidant activity, and anti-peptic ulcer properties, are targeting the digestive wellness and blood glucose regulation markets. With strong market fundamentals and global tea popularity, the venture has potential to reach a $1 billion market valuation.

Bon Natural Life Limited (BON) has announced an exclusive cooperation agreement with Beijing Huahai Keyuan for the distribution of its postbiotic hypoglycemic ingredients. The agreement spans 36 months with a contract value of $32 million. BON's patented product is designed to regulate blood sugar and control post-meal glucose spikes, offering advantages in safety and convenience.

The company is targeting the postprandial blood glucose control market, which has a size of over $30 billion and maintains a 7.5% compound annual growth rate. BON expects significant market advancement and growth in sales and profits over the next 2-3 years through this product line.

Bon Natural Life Limited (BON) has announced a 1-for-25 reverse stock split effective May 19, 2025, at 12:01 a.m. Eastern Time. The reverse split is primarily aimed at maintaining Nasdaq listing compliance by meeting the $1.00 minimum bid price requirement. Following the split, each 25 existing Class A ordinary shares will be consolidated into one new share, with fractional shares rounded up.

The company will maintain its "BON" trading symbol on Nasdaq with a new CUSIP number G14492204. Additionally, BON's authorized share capital will increase to 1 billion Class A ordinary shares, 50 million Class B shares, and 50 million preference shares. The Class B shares' conversion ratio to Class A shares will change from 1:1 to 1:25.

BON Natural Life Limited (Nasdaq: BON) has announced the launch of its innovative sleep health product series, featuring a patent-pending "Glucoraphanin-Myrosinase" delivery system. This breakthrough technology aims to enhance the bio-availability of glucoraphanin, a key compound found in broccoli that converts to sulforaphane in the body.

The company's proprietary system addresses the inefficient enzymatic conversion of glucoraphanin to sulforaphane, which typically limits the body's ability to access broccoli's full health benefits. Sulforaphane is associated with multiple health advantages, including sleep regulation, anti-cancer properties, and neuro-protective effects.

CEO Yongwei Hu emphasizes that BON's new sleep health products are designed to outperform traditional formulations through superior bio-availability and enhanced biological potency, positioning the company to capitalize on market opportunities in the sleep health sector.

Bon Natural Life Limited (BON) has received two delisting notifications from Nasdaq. The first notification on April 29, 2025, cited non-compliance with the Minimum Bid Price Requirement as BON's shares traded below $1.00 for 30 consecutive business days. Additionally, the stock traded at $0.10 or less for 10 consecutive days, making it ineligible for a compliance period. The second notification on May 1, 2025, indicated Nasdaq's determination to delist BON due to public interest concerns related to the company's March 2025 best efforts offering. BON has filed an appeal and requested a hearing, which temporarily stays the delisting process pending the Panel's decision.

Bon Natural Life (BON) has secured a significant $12 million 24-month supply agreement with Shanghai Yunsheng to co-develop apple polyphenol-infused health solutions. The partnership focuses on combining BON's patented extraction technology for antioxidant-rich apple polyphenols with plant-based proteins.

The initiative targets multiple health benefits including weight management, metabolic health, lipid management, and reduction of age-related muscle atrophy. Market validation shows similar apple polyphenol blends generating $40 million in recurring revenue, with monthly sales exceeding 500,000 units.

BON aims to capitalize on this high-growth market through dual revenue streams: standalone nutraceuticals and functional food additives, while maintaining strong profit margins.